Macquarie Group’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Macquarie Group’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-504,000	Closed	-$5.09M	–	1810
2022 Q4	$5.09M	Hold	504,000	–	–	0.01%	979
2022 Q3	$5M	Hold	504,000	–	–	0.01%	991
2022 Q2	$4.93M	Hold	504,000	–	–	0.01%	1037
2022 Q1	$4.91K	Hold	504,000	–	–	﹤0.01%	1120
2021 Q4	$4.88M	Hold	504,000	–	–	﹤0.01%	1125
2021 Q3	$4.87M	Buy	+504,000	New	+$4.87M	﹤0.01%	1111

Macquarie Group's EBAC Position: Q1 2023 in Review

Macquarie Group sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 504,000 shares — an estimated $5.09M sold.

Macquarie Group first reported a position in EBAC in Q3 2021 and held it in 6 quarters. The position peaked at $5.09M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Macquarie Group reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Macquarie Group sold 504,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $5.09M.
Macquarie Group first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2021 and held it in 6 quarters.
Macquarie Group's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $5.09M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Macquarie Group's 13F filing for Q1 2023, filed 15 May 2023.